Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
2 reports, 1 independent
Updated Aug 14
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Fate Therapeutics announced from its operational base that it is targeting the U.S. market for clinical trials.Sub-event
Fate Therapeutics seeks accelerated regulatory pathway support from the FDA.1 source
Keep exploring
The entities involved
-
Fate Therapeutics
a clinical-stage biopharmaceutical company in San Diego, United States
Nothing else this week.
- FDA
Related events
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
- FDA approval enables commercial opportunity involving CBRE Group.